NEKTAR THERAPEUTICS INDIA PVT LTD

Company Type: Factory (or more accurately, a research and development and/or manufacturing facility)

Company Introduction:

Nektar Therapeutics India Pvt Ltd is the Indian subsidiary of Nektar Therapeutics, a global biopharmaceutical company headquartered in San Francisco, California, USA. Nektar Therapeutics is dedicated to discovering and developing innovative new medicines for patients with debilitating diseases. The company primarily focuses on areas such as immunology, oncology, and virology.

As a key part of a global biopharmaceutical organization, Nektar Therapeutics India Pvt Ltd is involved in various stages of drug development and production. Its operations typically encompass research and development activities, support for clinical trials, and potentially manufacturing operations to contribute to the parent company's global supply chain or to cater to regional market demands. It functions as an integral part of the drug creation and production process rather than solely as a trading company that buys and sells finished goods from other manufacturers.

NEKTAR THERAPEUTICS INDIA PVT LTD primarily supports the global research and development efforts of its parent company, Nektar Therapeutics, a biopharmaceutical company focused on developing novel drug candidates. As such, it does not typically manufacture or sell a broad range of finished pharmaceutical products in India for the Indian market. The products associated with Nektar Therapeutics are drug candidates in various stages of clinical development, primarily in oncology and autoimmune diseases. These include Rezpegaldesleukin also known as NKTR-358, and NKTR-255. Bempegaldesleukin, also known as NKTR-214, was a significant drug candidate, though its development in partnership with Bristol Myers Squibb for certain indications has been discontinued.